JGB

Bill Gross Releases New Investment Outlook, 'Status Quo'

Retrieved on: 
Friday, July 21, 2023
JGB, Policy, Medicare, Fed, FF, ECB, Security (finance), Medicaid

LAGUNA BEACH, Calif., July 21, 2023 /PRNewswire/ -- Legendary bond and fixed income investor William H. (Bill) Gross today released a new Investment Outlook , "Status Quo".

Key Points: 
  • LAGUNA BEACH, Calif., July 21, 2023 /PRNewswire/ -- Legendary bond and fixed income investor William H. (Bill) Gross today released a new Investment Outlook , "Status Quo".
  • Gross writes that with inflation back to around 3% and the Fed nearing the end of its tightening cycle, it would appear to many that a new bond bull market is about to begin.
  • Gross doesn't agree: "While I think that the 10 year at 3.80% may have peaked at 4% for 2023, a bull market is not in the cards," he writes.
  • Full text of Bill Gross's July 21, 2023, Investment Outlook can be found at his website .

Arkon Energy Bolsters Global Expansion with $26 Million Capital Raise

Retrieved on: 
Tuesday, June 20, 2023
M&A, Data center infrastructure efficiency, Acquisition, JGB, Climate, Cryptocurrency, Arkon

MELBOURNE, Australia, June 20, 2023 /PRNewswire/ -- Arkon Energy Pty Ltd (Arkon), a global data center infrastructure company, today announced the successful completion of a $26 million capital raise with new funding being provided by Sandton Capital Partners, a global credit-oriented asset manager and participation from JGB Management, an existing lender to Arkon. The investment into Arkon is set to bolster the company's strategic growth and expansion on an international scale.

Key Points: 
  • Strategic investment to accelerate global expansion, reinforcing Arkon's position as a leader in Data Center Infrastructure
    MELBOURNE, Australia, June 20, 2023 /PRNewswire/ -- Arkon Energy Pty Ltd (Arkon), a global data center infrastructure company, today announced the successful completion of a $26 million capital raise with new funding being provided by Sandton Capital Partners, a global credit-oriented asset manager and participation from JGB Management, an existing lender to Arkon.
  • "This successful raise of $26 million marks a significant milestone for Arkon Energy and will act as the linchpin for our aggressive expansion into North America.
  • Barker's Point Capital Advisors acted as exclusive financial advisor to Arkon Energy in connection with arranging financing for the transaction.
  • Cohen & Company Capital Markets, a division of J.V.B Financial, LLC, serves as M&A advisor to Arkon Energy in connection with the acquisition of North American assets.

Aspen Group, Inc. Announces Closing of $12.4 Million Private Placement

Retrieved on: 
Tuesday, May 16, 2023
OTC Markets Group, AGI, Marketing, Aspen University, Family nurse practitioner, JGB, Security (finance), Adjustment

AGI also issued the investors a total of 2.2 million five-year warrants.

Key Points: 
  • AGI also issued the investors a total of 2.2 million five-year warrants.
  • The Company intends to use the proceeds from the private placement to refinance existing debt and for working capital purposes.
  • Michael Mathews, Chairman and CEO of Aspen Group, stated, "We are thrilled to announce the successful closure of this financing with the JGB team, which has significantly improved Aspen Group's financial position.
  • This will enable us to effectively manage changes in the timing of financial aid-related cash flow and pay off our outstanding $5 million line of credit.

Ault Alliance Announces Share Buyback of up to 333,333,333 Shares of Common Stock at $0.15 per Share Through Exchange Offer for New Class of Preferred Stock

Retrieved on: 
Friday, March 31, 2023
Professional Services, Technology, Cryptocurrency, Other Technology, Finance, Fintech, Common stock, TD Ameritrade, Calendar, Expiration date, Bangladesh Securities and Exchange Commission, Sale, Schedule, Expiration, VWAP, OTC, JGB, Security (finance), Letter, Georgeson, NYSE, Robin Hood, Common, Series, Fidelity

Ault Alliance, Inc. (“Ault Alliance” or the “Company”) (NYSE American: AULT), announced today that it is commencing an offer (the “Offer”) to holders of Ault Alliance’s outstanding shares of Class A Common Stock (the “Common Stock”), to exchange up to 333,333,333 shares of Common Stock for up to $50,000,000 aggregate liquidation preference of its 10.00% Series H Cumulative Redeemable Perpetual Preferred Stock (“Series H Preferred Stock”), with each 200 shares of Common Stock being exchangeable in the Offer for three shares of Series H Preferred Stock having a liquidation preference of $10.00 per share of Series H Preferred Stock (an effective price of $0.15 per share of Common Stock).

Key Points: 
  • Ault Alliance, Inc. (“Ault Alliance” or the “Company”) (NYSE American: AULT), announced today that it is commencing an offer (the “Offer”) to holders of Ault Alliance’s outstanding shares of Class A Common Stock (the “Common Stock”), to exchange up to 333,333,333 shares of Common Stock for up to $50,000,000 aggregate liquidation preference of its 10.00% Series H Cumulative Redeemable Perpetual Preferred Stock (“Series H Preferred Stock”), with each 200 shares of Common Stock being exchangeable in the Offer for three shares of Series H Preferred Stock having a liquidation preference of $10.00 per share of Series H Preferred Stock (an effective price of $0.15 per share of Common Stock).
  • If Common Stock tendered is freely tradable, the Series H Preferred Stock received in the exchange will be freely tradable.
  • If the Common Stock tendered in the exchange is restricted, the Series H Preferred Stock will be restricted to the same degree.
  • The maximum number of shares of Common Stock that may be exchanged into Series H Preferred Stock in the Offer is 333,333,333.

ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland

Retrieved on: 
Friday, February 24, 2023
SIX Swiss Exchange, Ernest Loumaye, JGB, Interim, Fertilisation, Retirement, Commonwealth of Australia (US securities entity), Form 10-K, Senior, Catarina, Cryptocurrency, Management, Security (finance)

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced a strategic reorganization that will consolidate operations in Switzerland so as to preserve cash, focus resources towards the development of nolasiban, a novel, oral oxytocin receptor agonist to improve in vitro fertilization success rates, and manage its out-licensed programs.
  • “The Board believes we are better positioned to deliver shareholder value following these difficult reorganization decisions.
  • The Company has initiated a search for a permanent Chief Executive Officer to be based in Geneva, Switzerland.
  • ObsEva intends to maintain its SIX Swiss Exchange listing and to continue to trade under the ticker symbol OBSN.

TRADITION DATA LAUNCHES JAPANESE GOVERNMENT BOND MARKET DATA PRODUCT

Retrieved on: 
Wednesday, February 1, 2023
IDB, Bank of Japan, JGB, Compagnie Française d'Assurance pour le Commerce Extérieur, Government, Risk, Intelligence, Bioinformatics, Policy, Dislocation, Inter-dealer broker, Bank, Security (finance), Renewable energy

LONDON, Feb. 1, 2023 /PRNewswire/ -- TraditionDATA, the market leading data and intelligence division of Compagnie Financière Tradition ("Tradition"), has launched a new Japanese Government Bond ("JGB") data product.  This will provide precise, intra-day, indicative market data and access to all issues across the JGB yield curve, offering a more accurate, timely, and credible alternative to the majority of aggregate-based data packages currently available.

Key Points: 
  • LONDON, Feb. 1, 2023 /PRNewswire/ -- TraditionDATA, the market leading data and intelligence division of Compagnie Financière Tradition ("Tradition"), has launched a new Japanese Government Bond ("JGB") data product.
  • This new product, based on data taken directly from UEDA Tradition's trading desk and analytics team in Tokyo, will provide the much-needed data for global fixed income investors and managers seeking insight into the world's second largest government bond market.
  • With nearly four decades of operating a leading bond market desk in Tokyo, TraditionDATA noted the strong customer demand for accurate, IDB-sourced independent data in an otherwise opaque market.
  • Some further volatility and dislocations are expected in the Japanese bond market, which has been marked by ongoing instability.

ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, December 1, 2022
Risk, SIX Swiss Exchange, Research, Drug development, Security (finance), Cleveland Cultural Gardens, Retirement, Workforce, Coronavirus, Amendment, Forbearance, Clinical trial, Pregnancy, Safety, Pharmacokinetics, IND, Female, BioScience, Center for Drug Evaluation and Research, Sale, Fertilisation, Woman, JGB, Cryptocurrency, Birth control, Pharmaceutical industry, Kissei, Yu Garden

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    GENEVA, Switzerland December 1, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (ObsEva or the Company), a biopharmaceutical company developing novel therapies for womens health, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.
  • Financial Results for the Third Quarter Ended September 30, 2022
    ObsEva had cash and cash equivalents of $9.7 million at September 30, 2022 compared to $54.7 million at December 31, 2021.
  • The third quarter 2022 financial statements can be accessed in the financial reports section here of the Companys website, or directly here .
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

Retrieved on: 
Tuesday, November 22, 2022
Report, Pharmacokinetics, Risk, Merck Group, Female, SIX Swiss Exchange, Consent, Birth certificate, Inflammation, Drug development, Security (finance), Center for Drug Evaluation and Research, Letter, Sale, Fertilisation, Coronavirus, Woman, Cleveland Cultural Gardens, Pregnancy, Amendment, Safety, Form 6-K, JGB, Life insurance, Pharmaceutical industry, Organon

The sale of the Ebopiprant license agreement both strengthens our immediate financial position, while providing the potential for future upside for shareholders,said Brian OCallaghan, CEO of ObsEva.

Key Points: 
  • The sale of the Ebopiprant license agreement both strengthens our immediate financial position, while providing the potential for future upside for shareholders,said Brian OCallaghan, CEO of ObsEva.
  • ObsEva retains worldwide, exclusive, commercial rights for nolasiban, except for the Peoples Republic of China.
  • In addition to the $15 million received in upfront proceeds, ObsEva is eligible to receive up to $98 million upon the achievement of certain development and regulatory milestones and sales milestones under the Companys license agreement with Organon for Ebopiprant that was sold to XOMA in the transaction.
  • In July 2021, ObsEva granted a license to Organon for the global development, manufacturing, and commercial rights to Ebopiprant.

ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings

Retrieved on: 
Wednesday, October 26, 2022
IND, Sister republic, SEC, Company, Drug development, Security (finance), Achievement, NASDAQ, Private Securities Litigation Reform Act, Investor, U.S. Securities and Exchange Commission, CEO, JGB, Risk, Coronavirus, Pregnancy, Contract, SIX Swiss Exchange, Hearing, Program, Birth certificate, Report, Compliance, Fertilisation, Woman, Fine chemical, Online gambling, Pharmaceutical industry, Nasdaq, Kissei

These assignments represent savings of approximately $16.0 million in contractual commitments, including $3.7 million of accounts payable.

Key Points: 
  • These assignments represent savings of approximately $16.0 million in contractual commitments, including $3.7 million of accounts payable.
  • On October 20, 2022, ObsEva attended its first hearing with the competent court in Geneva, Switzerland.
  • The Company continues to progress various corporate initiatives intended to resolve its over-indebtedness and support future pipeline development.
  • ObsEva retains worldwide, exclusive, commercial rights, except for the Peoples Republic of China which has been sub-licensed to YuYuan BioScience.

PARTS iD Announces New Term Loan Financing

Retrieved on: 
Wednesday, October 26, 2022
Online Retail, Aftermarket, Retail, Automotive, General Automotive, Technology, Electronic Commerce, U.S. Securities and Exchange Commission, Time, SEC, Growth, Advertising, E-commerce, Policy, NYSE, Security (finance), JGB, Technology, Private Securities Litigation Reform Act, Company, Industry, CEO, Exchange, Environment, Intellectual property, Digital, COVID-19, LLP, ID, Algorithm, Leadership, Bank, Risk management, Google

PARTS iD, Inc. (NYSE American: ID) (PARTS iD or Company), the owner and operator of, among other verticals, CARiD.com, a leading digital commerce platform for the automotive aftermarket, today announced a new $5.5 million senior secured term loan with JGB Capital, LLP (JGB).

Key Points: 
  • PARTS iD, Inc. (NYSE American: ID) (PARTS iD or Company), the owner and operator of, among other verticals, CARiD.com, a leading digital commerce platform for the automotive aftermarket, today announced a new $5.5 million senior secured term loan with JGB Capital, LLP (JGB).
  • We are pleased to partner with JGB Capital to strengthen our balance sheet and help fund our strategic initiatives, said Nino Ciappina, CEO of PARTS iD, Inc.
  • The initial term loan matures in October 2025 and bears interest at an annual rate of 8.00%.
  • PARTS iD is a technology-driven, digital commerce company focused on creating custom infrastructure and unique user experiences within niche markets.